199 related articles for article (PubMed ID: 29079774)
1. Promoter DNA methylation analysis reveals a novel diagnostic CpG-based biomarker and RAB25 hypermethylation in clear cell renel cell carcinoma.
Gu Y; Zou YM; Lei D; Huang Y; Li W; Mo Z; Hu Y
Sci Rep; 2017 Oct; 7(1):14200. PubMed ID: 29079774
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of Gremlin1 (GREM1) promoter CpG island hypermethylation in clear cell renal cell carcinoma.
van Vlodrop IJ; Baldewijns MM; Smits KM; Schouten LJ; van Neste L; van Criekinge W; van Poppel H; Lerut E; Schuebel KE; Ahuja N; Herman JG; de Bruïne AP; van Engeland M
Am J Pathol; 2010 Feb; 176(2):575-84. PubMed ID: 20042676
[TBL] [Abstract][Full Text] [Related]
3. DNA methylation associates with survival in non-metastatic clear cell renal cell carcinoma.
Evelönn EA; Landfors M; Haider Z; Köhn L; Ljungberg B; Roos G; Degerman S
BMC Cancer; 2019 Jan; 19(1):65. PubMed ID: 30642274
[TBL] [Abstract][Full Text] [Related]
4. DNA methylation of the SLC16A3 promoter regulates expression of the human lactate transporter MCT4 in renal cancer with consequences for clinical outcome.
Fisel P; Kruck S; Winter S; Bedke J; Hennenlotter J; Nies AT; Scharpf M; Fend F; Stenzl A; Schwab M; Schaeffeler E
Clin Cancer Res; 2013 Sep; 19(18):5170-81. PubMed ID: 23881922
[TBL] [Abstract][Full Text] [Related]
5. Methylation of the CA9 promoter can modulate expression of the tumor-associated carbonic anhydrase IX in dense carcinoma cell lines.
Jakubicková L; Biesová Z; Pastoreková S; Kettmann R; Pastorek J
Int J Oncol; 2005 Apr; 26(4):1121-7. PubMed ID: 15754010
[TBL] [Abstract][Full Text] [Related]
6. Keap1/Nrf2 pathway in kidney cancer: frequent methylation of KEAP1 gene promoter in clear renal cell carcinoma.
Fabrizio FP; Costantini M; Copetti M; la Torre A; Sparaneo A; Fontana A; Poeta L; Gallucci M; Sentinelli S; Graziano P; Parente P; Pompeo V; De Salvo L; Simone G; Papalia R; Picardo F; Balsamo T; Flammia GP; Trombetta D; Pantalone A; Kok K; Paranita F; Muscarella LA; Fazio VM
Oncotarget; 2017 Feb; 8(7):11187-11198. PubMed ID: 28061437
[TBL] [Abstract][Full Text] [Related]
7. Protocadherin17 Promoter Methylation is a Potential Predictive Biomarker in Clear Cell Renal Cell Carcinoma.
Lin YL; Gui SL; Guo H; Ma JG; Li WP
Med Sci Monit; 2015 Sep; 21():2870-6. PubMed ID: 26404644
[TBL] [Abstract][Full Text] [Related]
8. Frequent epigenetic suppression of tumor suppressor gene glutathione peroxidase 3 by promoter hypermethylation and its clinical implication in clear cell renal cell carcinoma.
Liu Q; Jin J; Ying J; Sun M; Cui Y; Zhang L; Xu B; Fan Y; Zhang Q
Int J Mol Sci; 2015 May; 16(5):10636-49. PubMed ID: 25970749
[TBL] [Abstract][Full Text] [Related]
9. Development and confirmation of potential gene classifiers of human clear cell renal cell carcinoma using next-generation RNA sequencing.
Eikrem OS; Strauss P; Beisland C; Scherer A; Landolt L; Flatberg A; Leh S; Beisvag V; Skogstrand T; Hjelle K; Shresta A; Marti HP
Scand J Urol; 2016 Dec; 50(6):452-462. PubMed ID: 27739342
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of JAK3 promoter methylation and mRNA expression in clear cell renal cell carcinoma.
Long Q; Huang C; Huang J; Meng Q; Cheng Y; Li Y; He L; Chen M; Zhang C; Wang X; Zhu W; Peng J; Shi D; Zheng F; Dong P; Deng W
J Adv Res; 2022 Sep; 40():153-166. PubMed ID: 36100323
[TBL] [Abstract][Full Text] [Related]
11. A Four-Gene Promoter Methylation Marker Panel Consisting of
van Vlodrop IJH; Joosten SC; De Meyer T; Smits KM; Van Neste L; Melotte V; Baldewijns MMLL; Schouten LJ; van den Brandt PA; Jeschke J; Yi JM; Schuebel KE; Ahuja N; Herman JG; Aarts MJ; Bosman FT; Van Criekinge W; van Engeland M
Clin Cancer Res; 2017 Apr; 23(8):2006-2018. PubMed ID: 27756787
[No Abstract] [Full Text] [Related]
12. Downregulation of CLDN7 due to promoter hypermethylation is associated with human clear cell renal cell carcinoma progression and poor prognosis.
Li Y; Gong Y; Ning X; Peng D; Liu L; He S; Gong K; Zhang C; Li X; Zhou L
J Exp Clin Cancer Res; 2018 Nov; 37(1):276. PubMed ID: 30428910
[TBL] [Abstract][Full Text] [Related]
13. [MN/CA IX antigen as a potential target for renal cell carcinoma].
Uemura H; Cho M; Nakagawa Y; Shimizu K; Yoshikawa M; Kim S; Hirao Y
Hinyokika Kiyo; 2000 Oct; 46(10):745-8. PubMed ID: 11215204
[TBL] [Abstract][Full Text] [Related]
14. A CpG-methylation-based assay to predict survival in clear cell renal cell carcinoma.
Wei JH; Haddad A; Wu KJ; Zhao HW; Kapur P; Zhang ZL; Zhao LY; Chen ZH; Zhou YY; Zhou JC; Wang B; Yu YH; Cai MY; Xie D; Liao B; Li CX; Li PX; Wang ZR; Zhou FJ; Shi L; Liu QZ; Gao ZL; He DL; Chen W; Hsieh JT; Li QZ; Margulis V; Luo JH
Nat Commun; 2015 Oct; 6():8699. PubMed ID: 26515236
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of novel DNA methylation biomarkers for renal clear cell carcinoma.
Kubiliūtė R; Žukauskaitė K; Žalimas A; Ulys A; Sabaliauskaitė R; Bakavičius A; Želvys A; Jankevičius F; Jarmalaitė S
J Cancer Res Clin Oncol; 2022 Feb; 148(2):361-375. PubMed ID: 34689221
[TBL] [Abstract][Full Text] [Related]
16. Quantitative promoter methylation analysis of multiple cancer-related genes in renal cell tumors.
Costa VL; Henrique R; Ribeiro FR; Pinto M; Oliveira J; Lobo F; Teixeira MR; Jerónimo C
BMC Cancer; 2007 Jul; 7():133. PubMed ID: 17645803
[TBL] [Abstract][Full Text] [Related]
17. Hypomethylation of the MN/CA9 promoter and upregulated MN/CA9 expression in human renal cell carcinoma.
Cho M; Uemura H; Kim SC; Kawada Y; Yoshida K; Hirao Y; Konishi N; Saga S; Yoshikawa K
Br J Cancer; 2001 Aug; 85(4):563-7. PubMed ID: 11506497
[TBL] [Abstract][Full Text] [Related]
18. Identification of methylation-driven genes related to prognosis in clear-cell renal cell carcinoma.
Wang J; Zhang Q; Zhu Q; Liu C; Nan X; Wang F; Fang L; Liu J; Xie C; Fu S; Song B
J Cell Physiol; 2020 Feb; 235(2):1296-1308. PubMed ID: 31273792
[TBL] [Abstract][Full Text] [Related]
19. Promoter hypermethylation profile of kidney cancer with new proapoptotic p53 target genes and clinical implications.
Christoph F; Weikert S; Kempkensteffen C; Krause H; Schostak M; Köllermann J; Miller K; Schrader M
Clin Cancer Res; 2006 Sep; 12(17):5040-6. PubMed ID: 16951219
[TBL] [Abstract][Full Text] [Related]
20. Tumor-specific isoform switch of the fibroblast growth factor receptor 2 underlies the mesenchymal and malignant phenotypes of clear cell renal cell carcinomas.
Zhao Q; Caballero OL; Davis ID; Jonasch E; Tamboli P; Yung WK; Weinstein JN; ; Strausberg RL; Yao J
Clin Cancer Res; 2013 May; 19(9):2460-72. PubMed ID: 23444225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
